Ovarian Cancer Education
Ovarian cancer management has been reshaped by PARP inhibitor maintenance, HRD testing, and evolving surgical paradigms. Knowledge Med sessions help community providers work through complex treatment decisions using interactive case simulations led by gynecologic oncology specialists.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing ovarian cancer face evolving treatment decisions that interactive, independently reviewed education can help address.
- Selecting maintenance therapy based on BRCA/HRD status
- Deciding between primary debulking and neoadjuvant chemotherapy
- Managing platinum-sensitive vs platinum-resistant recurrence
- Integrating bevacizumab and emerging targeted agents
What Sessions Cover
Knowledge Med Ovarian Cancer sessions use interactive case simulations to address these topics and more.
- First-line treatment and PARP inhibitor maintenance in ovarian cancer
- HRD testing: interpretation and impact on treatment selection
- Management of recurrent ovarian cancer across platinum intervals
- Emerging therapies: ADCs, folate receptor-targeted agents, and combinations
Interactive Ovarian Cancer Sessions
Case Simulations
Work through realistic ovarian cancer patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key Ovarian Cancer clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a Ovarian Cancer Session
Third-party, non-promotional ovarian cancer education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session